On Friday, Johnson & Johnson (NYSE: JNJ) opened lower -0.36% from the last session, before settling in for the closing price of $145.58. Price fluctuations for JNJ have ranged from $142.75 to $168.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 1.31%. Company’s average yearly earnings per share was noted 0.36% at the time writing. With a float of $2.40 billion, this company’s outstanding shares have now reached $2.41 billion.
The extent of productivity of a business whose workforce counts for 131900 workers is very important to gauge. In terms of profitability, gross margin is 69.05%, operating margin of 25.22%, and the pretax margin is 20.1%.
Johnson & Johnson (JNJ) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Johnson & Johnson is 0.12%, while institutional ownership is 72.75%. The most recent insider transaction that took place on Dec 12 ’24, was worth 147,220. In this transaction Director of this company bought 1,000 shares at a rate of $147.22, taking the stock ownership to the 1,000 shares. Before that another transaction happened on Dec 04 ’24, when Company’s Former Officer proposed sale 25,742 for $149.90, making the entire transaction worth $3,858,598.
Johnson & Johnson (JNJ) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.64 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.00% during the next five years compared to -0.27% drop over the previous five years of trading.
Johnson & Johnson (NYSE: JNJ) Trading Performance Indicators
Check out the current performance indicators for Johnson & Johnson (JNJ). In the past quarter, the stock posted a quick ratio of 0.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.97. Likewise, its price to free cash flow for the trailing twelve months is 16.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 6.05, a number that is poised to hit 2.02 in the next quarter and is forecasted to reach 10.58 in one year’s time.
Technical Analysis of Johnson & Johnson (JNJ)
The latest stats from [Johnson & Johnson, JNJ] show that its last 5-days average volume of 7.97 million was superior to 7.18 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 58.58%. Additionally, its Average True Range was 2.17.
During the past 100 days, Johnson & Johnson’s (JNJ) raw stochastic average was set at 8.81%, which indicates a significant decrease from 28.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 14.90% in the past 14 days, which was higher than the 12.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $153.88, while its 200-day Moving Average is $154.60. Now, the first resistance to watch is $146.21. This is followed by the second major resistance level at $147.36. The third major resistance level sits at $148.13. If the price goes on to break the first support level at $144.29, it is likely to go to the next support level at $143.52. The third support level lies at $142.37 if the price breaches the second support level.
Johnson & Johnson (NYSE: JNJ) Key Stats
There are currently 2,407,623K shares outstanding in the company with a market cap of 347.95 billion. Presently, the company’s annual sales total 85,159 M according to its annual income of 35,153 M. Last quarter, the company’s sales amounted to 22,471 M and its income totaled 2,694 M.
